| Overview |
| bs-11202R-Cy3 |
| NR2E1/Tailless Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Chicken, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NR2E1/Tailless |
| 321-385/385 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Nucleus |
| hTll; nr2e1; NR2E1_HUMAN; Nuclear receptor subfamily 2 group E member 1; Nuclear receptor TLX; Orphan nuclear receptor NR2E1; Protein tailless homolog; Tailless homolog; Tll; TLX; XTLL. |
| NR2 proteins are a large family of nuclear hormone receptor transcription factors. The proteins belonging to this family are characterized by discrete domains functioning in DNA and ligand binding. NR2E1 (nuclear receptor subfamily 2, group E, member 1), also known as TLX, is an essential component in the formation of synaptic plasticity and dendritic structure in retinal astrocytes. In addition, NR2E1 is a orphan receptor that binds DNA as part of the hormone response element (HRE), a transcription regulator for hormones. DNA-binding orphan receptors have the conserved sequence 5'-AAGGTCA-3', a motif that determines substrate binding specificity. NR2E1 is expressed in brain tissue, with highest levels in astrocytes, and is localized to the nucleus. Mutations in the gene that encodes NR2E1 may lead to retinal dystrophy, a disorder characterized by a reduction in the thickness of the retina. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz